Cabergoline

Cabergoline
Clinical data
Trade names	Dostinex, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Cabergoline;
Routes of; administration	By mouth
ATC code	G02CB03 (WHO) N04BC06 (WHO);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	First-pass effect seen; absolute bioavailability unknown
Protein binding	Moderately bound (40–42%); concentration-independent
Metabolism	Liver, predominately via hydrolysis of the acylurea bond or the urea moiety
Elimination half-life	63–69 hours (estimated)
Excretion	Urine (22%), feces (60%)
Identifiers
	IUPAC name (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	81409-90-7 ;
PubChem CID	54746;
IUPHAR/BPS	37;
DrugBank	DB00248 ;
ChemSpider	49452 ;
UNII	LL60K9J05T;
KEGG	D00987 ;
ChEBI	CHEBI:3286 ;
ChEMBL	ChEMBL1201087 ;
CompTox Dashboard (EPA)	DTXSID6022719 ;
ECHA InfoCard	100.155.380
Chemical and physical data
Formula	C26H37N5O2
Molar mass	451.615 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@]12C[C@@H](C(=O)N(CCCN(C)C)C(=O)NCC)CN(CC=C)[C@]1([H])Cc3c[nH]c4cccc2c34;
	InChI InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 ; Key:KORNTPPJEAJQIU-KJXAQDMKSA-N ;
	(what is this?) (verify)

Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth.

Cabergoline is an ergot derivative and a potent dopamine D₂ receptor agonist.

Cabergoline was patented in 1980 and approved for medical use in 1993. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.